Postenucleation adjuvant chemotherapy with vincristine, etoposide, and carboplatin for the treatment of high-risk retinoblastoma

Archives of Ophthalmology

Volumn 129, Issue 11, 2011, Pages 1422-1427

  Kaliki, Swathi ^a   Shields, Carol L ^a   Shah, Sanket U ^a   Eagle Jr , Ralph C ^a   Shields, Jerry A ^a   Leahey, Ann ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; ETOPOFOS; VINCRISTINE SULFATE;

ADJUVANT THERAPY; ANTERIOR EYE SEGMENT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER RISK; CHILD; CONTROLLED STUDY; DRUG EFFICACY; ENUCLEATION; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFANT; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; OPTIC NERVE; ORBIT; PNEUMONIA; POSTOPERATIVE CARE; PRESCHOOL CHILD; PRIORITY JOURNAL; RETINOBLASTOMA; RETROSPECTIVE STUDY; RISK FACTOR; SCLERA; UVEA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; CHILD, PRESCHOOL; ETOPOSIDE; EYE ENUCLEATION; FEMALE; HUMANS; INFANT; MALE; NEOPLASM INVASIVENESS; OPTIC NERVE NEOPLASMS; POSTOPERATIVE CARE; RETINAL NEOPLASMS; RETINOBLASTOMA; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; UVEAL NEOPLASMS; VINCRISTINE;

EID: 81355133299     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2011.289     Document Type: Article

References (33)

1. Kivelä T. The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death. Br J Ophthalmol. 2009;93(9):1129-1131.
2. Broaddus E, Topham A, Singh AD. Incidence of retinoblastoma in the USA: 1975-2004. Br J Ophthalmol. 2009;93(1):21-23.
3. Broaddus E, Topham A, Singh AD. Survival with retinoblastoma in the USA: 1975-2004. Br J Ophthalmol. 2009;93(1):24-27.
4. MacKay CJ, Abramson DH, Ellsworth RM. Metastatic patterns of retinoblastoma. Arch Ophthalmol. 1984;102(3):391-396. (Pubitemid 14197287)
5. Kopelman JE, McLean IW, Rosenberg SH. Multivariate analysis of risk factors for metastasis in retinoblastoma treated by enucleation. Ophthalmology. 1987;94(4):371-377. (Pubitemid 17056025)
6. Shields CL, Shields JA, Baez K, Cater JR, De Potter P. Optic nerve invasion of retinoblastoma: metastatic potential and clinical risk factors. Cancer. 1994;73(3):692-698. (Pubitemid 24046614)
7. Shields CL, Shields JA, Baez KA, Cater J, De Potter PV. Choroidal invasion of retinoblastoma: metastatic potential and clinical risk factors. Br J Ophthalmol. 1993;77(9):544-548. (Pubitemid 23281450)
8. Messmer EP, Heinrich T, Höpping W, de Sutter E, Havers W, Sauerwein W. Risk factors for metastases in patients with retinoblastoma. Ophthalmology. 1991;98(2):136-141.
9. Khelfaoui F, Validire P, Auperin A, et al. Histopathologic risk factors in retinoblastoma: a retrospective study of 172 patients treated in a single institution. Cancer. 1996;77(6):1206-1213. (Pubitemid 26080915)
10. Honavar SG, Singh AD, Shields CL, et al. Postenucleation adjuvant therapy in high-risk retinoblastoma. Arch Ophthalmol. 2002;120(7):923-931. (Pubitemid 34755545)
11. Sastre X, Chantada GL, Doz F, et al. International Retinoblastoma Staging Working Group. Proceedings of the consensus meetings from the International Retinoblastoma Staging Working Group on the pathology guidelines for the examination of enucleated eyes and evaluation of prognostic risk factors in retinoblastoma. Arch Pathol Lab Med. 2009;133(8):1199-1202.
12. Chantada GL, Doz F, Orjuela M, et al. International Retinoblastoma Staging Working Group. World disparities in risk definition and management of retinoblastoma: a report from the International Retinoblastoma Staging Working Group. Pediatr Blood Cancer. 2008;50(3):692-694. (Pubitemid 351155863)
13. Chantada GL, Dunkel IJ, de Dávila MT, Abramson DH. Retinoblastoma patients with high risk ocular pathological features: who needs adjuvant therapy? Br J Ophthalmol. 2004;88(8):1069-1073. (Pubitemid 39013152)
14. Makimoto A. Results of treatment of retinoblastoma that has infiltrated the optic nerve, is recurrent, or has metastasized outside the eyeball. Int J Clin Oncol. 2004;9(1):7-12. (Pubitemid 38470657)
15. Young JJL, Smith MA, Roffers SD, et al. Retinoblastoma. In: Ries LAG, Smith MA, Gurney JG, eds, et al. Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975-1995, SEER Program. Bethesda, MD: National Cancer Institute; 1999. NIH Publication 99-4649.
16. Eagle RC Jr. High-risk features and tumor differentiation in retinoblastoma: a retrospective histopathologic study. Arch Pathol Lab Med. 2009;133(8):1203-1209.
17. Gupta R, Vemuganti GK, Reddy VA, Honavar SG. Histopathologic risk factors in retinoblastoma in India. Arch Pathol Lab Med. 2009;133(8):1210-1214.
18. Magramm I, Abramson DH, Ellsworth RM. Optic nerve involvement in retinoblastoma. Ophthalmology. 1989;96(2):217-222. (Pubitemid 19049464)
19. Wolff JA, Pratt CB, Sitarz AL. Chemotherapy of metastatic retinoblastoma. Cancer Chemother Rep. 1962;16:435-437.
20. Lonsdale D, Berry DH, Holcomb TM, et al. Chemotherapeutic trials in patients with metastatic retinoblastoma. Cancer Chemother Rep. 1968;52(6):631-634.
21. Hayman GA, Ellsworth RM, Feind CR, Tretter P. Combination therapy in retinoblastoma: a 15-year summary of methods and results. Arch Ophthalmol. 1968;80:744-746.
22. White L. Chemotherapy for retinoblastoma: where do we go from here? a review of published literature and meeting abstracts, including discussions during the Vth International Symposium on Retinoblastoma, October 1990. Ophthalmic Paediatr Genet. 1991;12(3):115-130.
23. Chan HSL, Gallie BL, Munier FL, Beck Popovic M. Chemotherapy for retinoblastoma. Ophthalmol Clin North Am. 2005;18(1):55-63, viii. (Pubitemid 40348810)
24. Howarth C, Meyer D, Hustu HO, Johnson WW, Shanks E, Pratt C. Stage-related combined modality treatment of retinoblastoma: results of a prospective study. Cancer. 1980;45(5):851-858. (Pubitemid 10129832)
25. Wolff JA, Boesel CP, Dyment PG, et al. Treatment of retinoblastoma: a preliminary report. In: Raybaud C, Clement R, Lebreuil G, et al., eds. International Congress Series 570: Pediatric Oncology: Proceedings XIVth Meeting International Society of Pediatric Oncology, Amsterdam. Princeton, NJ: Experta Medica; 1982:364-368.
26. Keith CG. Chemotherapy in retinoblastoma management. Ophthalmic Paediatr Genet. 1989;10(2):93-98. (Pubitemid 19142949)
27. Zelter M, Damel A, Gonzalez G, Schwartz L. A prospective study on the treatment of retinoblastoma in 72 patients. Cancer. 1991;68(8):1685-1690.
28. Schvartzman E, Chantada G, Fandiño A, de Dávila MT, Raslawski E, Manzitti J. Results of a stage-based protocol for the treatment of retinoblastoma. J Clin Oncol. 1996;14(5):1532-1536. (Pubitemid 26134210)
29. Namouni F, Doz F, Tanguy ML, et al. High-dose chemotherapy with carboplatin, etoposide and cyclophosphamide followed by a haematopoietic stem cell rescue in patients with high-risk retinoblastoma: a SFOP and SFGM study. Eur J Cancer. 1997;33(14):2368-2375. (Pubitemid 28129178)
30. Mustafa MM, Jamshed A, Khafaga Y, et al. Adjuvant chemotherapy with vincristine, doxorubicin, and cyclophosphamide in the treatment of postenucleation high risk retinoblastoma. J Pediatr Hematol Oncol. 1999;21(5):364-369. (Pubitemid 30306004)
31. Uusitalo MS, Van Quill KR, Scott IU, Matthay KK, Murray TG, O'Brien JM. Evaluation of chemoprophylaxis in patients with unilateral retinoblastoma with high-risk features on histopathologic examination. Arch Ophthalmol. 2001;119(1):41-48. (Pubitemid 32096384)
32. Cuenca A, Giron F, Castro D, et al. Microscopic scleral invasion in retinoblastoma: clinicopathological features and outcome. Arch Ophthalmol. 2009;127(8):1006-1010.
33. Shields CL, Shields JA. Retinoblastoma management: advances in enucleation, intravenous chemoreduction, and intra-arterial chemotherapy. Curr Opin Ophthalmol. 2010;21(3):203-212.